Abstract:Background aims: Mesenchymal stromal cells (MSCs) hold great promise in the treatment of diabetic retinopathy (DR), as evidenced by increasing preclinical and clinical studies. However, the absence of standardized and industrialized clinical-grade donor cells hampers the continued development and large-scale clinical application of MSCs-based therapies for DR. Previously, we have identified a unique population of MSCs generated from a clinical-grade human embryonic stem cell (hESC) line under Good Manufacturing Practice conditions that could be a potential source to address the issues. Here, we investigated the therapeutic potential of the clinical-grade hESC line-derived MSCs (hESC-MSCs) on db/db mice with DR. Methods: hESC-MSCs were initially characterized by morphological assessment, flow cytometry analysis and trilineage differentiation assays. These cells (5 × 106 cells) were then transplanted intravenously into 12-week-old db/db mice via tail vein, with phosphate-buffered saline transplantation and untreated groups used as controls. The retinal alterations in neural functions and microvascular perfusions, and inflammatory responses in peripheral blood and retina were evaluated at 4 and 6 weeks after transplantation using electroretinography, optical coherence tomography angiography and flow cytometry, respectively. Body weight and fasting blood glucose (FBG) levels were also measured to investigate their systemic implications. Results: Compared with controls, intravenous transplantation of hESC-MSCs could significantly: (i) enhance impaired retinal electroretinography functions (including amplitudes of a-, b-wave and oscillatory potentials) at 4 weeks after transplantation; (ii) alleviate microvascular dysfunctions, especially in the inner retina with significance (including reducing non-perfusion area and increasing vascular area density) at 4 weeks after transplantation; (iii) decrease FBG levels at 4 weeks after transplantation and induce weight loss up to 6 weeks after transplantation and (iv) increase both peripheral blood and retinal interleukin-10 levels at 4 weeks after transplantation and modulate peripheral blood inflammatory cytokines and chemokines levels, such as monocyte chemotactic protein-1, up to 6 weeks after transplantation. Conclusions: The findings of our study indicated that intravenous transplantation of hESC-MSCs ameliorated retinal neural and microvascular dysfunctions, regulated body weight and FBG and modulated peripheral blood and retinal inflammation responses in a mouse model of DR. These results suggest that hESC-MSCs could be a potentially effective clinical-grade cell source for the treatment of DR.

Suppression of Microrna-205-5p in Human Mesenchymal Stem Cells Improves Their Therapeutic Potential in Treating Diabetic Foot Disease

Improved therapeutic effects on diabetic foot by human mesenchymal stem cells expressing MALAT1 as a sponge for microRNA-205-5p.

Mesenchymal Stem Cells–microvesicle-Mir-451a Ameliorate Early Diabetic Kidney Injury by Negative Regulation of P15 and P19

Protective Effect and Molecular Mechanism of Mesenchymal Stem Cell-Derived Extracellular Vesicles in Diabetic Foot Ulcers.

Ameliorating Lung Fibrosis and Pulmonary Function in Diabetic Mice: Therapeutic Potential of Mesenchymal Stem Cell

Bone Marrow Mesenchymal Stem Cells Induce Angiogenesis and Attenuate the Remodeling of Diabetic Cardiomyopathy

Function and mechanism of mesenchymal stem cells in the healing of diabetic foot wounds

microRNA-15b-5p shuttled by mesenchymal stem cell-derived extracellular vesicles protects podocytes from diabetic nephropathy via downregulation of VEGF/PDK4 axis

MicroRNA-155 Inhibition Promoted Wound Healing in Diabetic Rats

Mesenchymal Stromal Cell-Derived Extracellular Vesicles in the Treatment of Diabetic Foot Ulcers: Application and Challenges

MSC Attenuate Diabetes-Induced Functional Impairment in Adipocytes Via Secretion of Insulin-Like Growth Factor-1.

Mir-199A-5p Plays a Pivotal Role on Wound Healing Via Suppressing VEGFA and ROCK1 in Diabetic Ulcer Foot

Advancements in diabetic foot ulcer research: Focus on mesenchymal stem cells and their exosomes

The Therapeutic Potential of Mesenchymal Stem Cells in the Treatment of Diabetes Mellitus.

Clinical-grade human embryonic stem cell-derived mesenchymal stromal cells ameliorate diabetic retinopathy in db/db mice

Diabetic microenvironment preconditioning of adipose tissue-derived mesenchymal stem cells enhances their anti-diabetic, anti-long-term complications, and anti-inflammatory effects in type 2 diabetic rats

MicroRNA-146a-5p-modified Human Umbilical Cord Mesenchymal Stem Cells Enhance Protection Against Renal Injury in Diabetic Nephropathy Through Facilitating M2 Macrophage Polarization by Targeting TRAF6

Angiogenic Effect Of Mesenchymal Stem Cells As A Therapeutic Target For Enhancing Diabetic Wound Healing

Mesenchymal stem cell therapy in diabetic foot ulcer: An updated comprehensive review

Paracrine effect of mesenchymal stem cell as a novel therapeutic strategy for diabetic nephropathy

MicroRNA-146a-5p-modified human umbilical cord mesenchymal stem cells enhance protection against diabetic nephropathy in rats through facilitating M2 macrophage polarization